Tekla Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $112M | Sell |
318,043
-12,300
| -4% | -$4.14M | 4.38% | 5 |
|
|
2023
Q1 | $104M | Hold |
330,343
| – | – | 3.96% | 6 |
|
|
2022
Q4 | $95.4M | Buy |
330,343
+16,940
| +5% | +$5.16M | 3.6% | 6 |
|
|
2022
Q3 | $90.7M | Sell |
313,403
-47,828
| -13% | -$13.8M | 3.71% | 5 |
|
|
2022
Q2 | $102M | Buy |
361,231
+52,347
| +17% | +$14M | 4% | 4 |
|
|
2022
Q1 | $80.6M | Buy |
308,884
+35,838
| +13% | +$8.51M | 2.83% | 8 |
|
|
2021
Q4 | $60M | Hold |
273,046
| – | – | 1.93% | 17 |
|
|
2021
Q3 | $49.5M | Sell |
273,046
-122,242
| -31% | -$23.9M | 1.59% | 17 |
|
|
2021
Q2 | $79.7M | Hold |
395,288
| – | – | 2.59% | 9 |
|
|
2021
Q1 | $84.9M | Buy |
395,288
+89,978
| +29% | +$19.8M | 2.92% | 6 |
|
|
2020
Q4 | $72.2M | Sell |
305,310
-96,050
| -24% | -$22M | 2.54% | 8 |
|
|
2020
Q3 | $109M | Sell |
401,360
-75,970
| -16% | -$21M | 4.09% | 3 |
|
|
2020
Q2 | $139M | Sell |
477,330
-8,400
| -2% | -$2.28M | 5.27% | 2 |
|
|
2020
Q1 | $116M | Sell |
485,730
-8,059
| -2% | -$1.85M | 5.23% | 3 |
|
|
2019
Q4 | $108M | Buy |
493,789
+6,555
| +1% | +$1.33M | 4.09% | 5 |
|
|
2019
Q3 | $82.5M | Sell |
487,234
-2,500
| -0.5% | -$442K | 3.6% | 6 |
|
|
2019
Q2 | $89.8M | Buy |
489,734
+46,022
| +10% | +$8.05M | 3.66% | 5 |
|
|
2019
Q1 | $81.6M | Buy |
443,712
+17,464
| +4% | +$3.23M | 3.31% | 7 |
|
|
2018
Q4 | $70.6M | Buy |
426,248
+18,013
| +4% | +$3.12M | 3.02% | 8 |
|
|
2018
Q3 | $78.7M | Sell |
408,235
-173,287
| -30% | -$30.9M | 2.85% | 8 |
|
|
2018
Q2 | $98.8M | Sell |
581,522
-32,562
| -5% | -$5.05M | 3.75% | 7 |
|
|
2018
Q1 | $100M | Sell |
614,084
-29,678
| -5% | -$4.85M | 3.89% | 6 |
|
|
2017
Q4 | $96.5M | Sell |
643,762
-87,361
| -12% | -$12.9M | 3.72% | 6 |
|
|
2017
Q3 | $111M | Sell |
731,123
-66,930
| -8% | -$10.1M | 3.97% | 5 |
|
|
2017
Q2 | $103M | Sell |
798,053
-235,450
| -23% | -$28.3M | 3.81% | 5 |
|
|
2017
Q1 | $113M | Hold |
1,033,503
| – | – | 4.38% | 4 |
|
|
2016
Q4 | $76.1M | Hold |
1,033,503
| – | – | 3.24% | 7 |
|
|
2016
Q3 | $90.1M | Hold |
1,033,503
| – | – | 3.47% | 6 |
|
|
2016
Q2 | $88.9M | Hold |
1,033,503
| – | – | 3.63% | 5 |
|
|
2016
Q1 | $82.2M | Hold |
1,033,503
| – | – | 3.49% | 6 |
|
|
2015
Q4 | $130M | Buy |
1,033,503
+23,600
| +2% | +$2.85M | 4.72% | 4 |
|
|
2015
Q3 | $105M | Buy |
1,009,903
+112,000
| +12% | +$14.4M | 3.78% | 4 |
|
|
2015
Q2 | $111M | Buy |
897,903
+433,659
| +93% | +$54.6M | 4.01% | 5 |
|
|
2015
Q1 | $54.8M | Sell |
464,244
-237,700
| -34% | -$28.5M | 2.17% | 14 |
|
|
2014
Q4 | $83.4M | Hold |
701,944
| – | – | 3.9% | 5 |
|
|
2014
Q3 | $78.8M | Buy |
701,944
+161,000
| +30% | +$15.3M | 3.7% | 3 |
|
|
2014
Q2 | $51.2M | Buy |
540,944
+41,180
| +8% | +$2.89M | 4.7% | 7 |
|
|
2014
Q1 | $35.3M | Hold |
499,764
| – | – | 3.53% | 8 |
|
|
2013
Q4 | $37.1M | Hold |
499,764
| – | – | 3.9% | 7 |
|
|
2013
Q3 | $37.9M | Buy |
499,764
+45,600
| +10% | +$3.63M | 4.22% | 7 |
|
|
2013
Q2 | $36.3M | Buy |
+454,164
| New | +$33.4M | 4.93% | 5 |
|
Other funds holding VRTX
Tekla Capital Management's VRTX Position: Q2 2023 in Review
Tekla Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q2 2023, selling an estimated $4.14M and leaving 318,043 shares worth $112M. The position accounts for 4.38% of the portfolio, ranked #5.
Tekla Capital Management first reported a position in VRTX in Q2 2013 and has held it in 41 quarters since. The position peaked at $139M in Q2 2020. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.
- Tekla Capital Management held 318,043 shares of Vertex Pharmaceuticals worth $112M as of Q2 2023.
- Tekla Capital Management sold 12,300 Vertex Pharmaceuticals shares in Q2 2023, an estimated $4.14M.
- Vertex Pharmaceuticals made up 4.38% of Tekla Capital Management's portfolio in Q2 2023, its #5 holding.
- Tekla Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Vertex Pharmaceuticals position peaked at $139M in Q2 2020.
- 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.